PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

NCT07739537 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Diabete Type 2
Pharmacogenomic Drug Interaction

Interventions

DRUG: Orforglipron

Sponsor

Massachusetts General Hospital